(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.
Rezolute's earnings in 2025 is -$77,184,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$80,960,408, with the lowest RZLT earnings forecast at -$109,047,578, and the highest RZLT earnings forecast at -$70,102,014. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$86,728,061, with the lowest RZLT earnings forecast at -$212,642,776, and the highest RZLT earnings forecast at -$52,576,511.
In 2028, RZLT is forecast to generate -$11,822,760 in earnings, with the lowest earnings forecast at -$59,067,438 and the highest earnings forecast at $49,655,593.